Technology News and Research

RSS

Quick-Med Technologies, Biosara sign development agreement

Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it has signed a development agreement with Biosara Corporation, a medical device company targeting wound dressings for major medical and healthcare providers, along with the multi-billion dollar organized sports athlete markets.

13 Aug 2010

PROFIT magazine ranks Prollenium as one of Canada's Fastest Growing Companies

Ario Khoshbin, President of Prollenium Medical Technologies Inc., a privately held specialty medical device company, reported today that his firm will continue to record strong year on year gains in revenues and profitability for its 2010 Fiscal Year ending June 30th. Over the past five years, Prollenium has recorded aggregate revenue growth of more than 524% ranking it amongst Canada's fastest growing firms.

13 Aug 2010

SANUWAVE second-quarter revenues decrease to $117,000

SANUWAVE Health, Inc., an emerging medical technology company focused on regenerative medicine, today reported financial results for the three and six months ended June 30, 2010 and provided a business update.

13 Aug 2010

First Edition: August 13, 2010

Today's headlines explore a variety of health policy issues, ranging from consumer protections regarding benefit rights to the cost of electronic medical records.

13 Aug 2010

General Dynamics awarded $80.3M contract to support HHS Early Retiree Reinsurance Program

General Dynamics Information Technology's ViPS, part of its Health IT Solutions business sector, has been awarded a contract to support the Department of Health and Human Services (HHS) Early Retiree Reinsurance Program (ERRP). The total potential contract value is $80.3 million over four years if all options are exercised.

13 Aug 2010

EUROPEAN BIOTECHNICA AWARD finalists announced

The names of the finalists in this year's EUROPEAN BIOTECHNICA AWARD have been announced. The companies Addex Pharmaceuticals (Switzerland), Apeiron Biologics (Austria) and Galapagos Genomics (Belgium) have made it through to the final round.

13 Aug 2010

UMass Memorial selects McKesson's CytoCare robot to automate compounding of hazardous IV drugs

UMass Memorial Medical Center in Massachusetts has selected the CytoCare™ robot from McKesson to automate the compounding of intravenous (IV) drugs. The robotic technology will enable the 830-bed facility to more safely prepare hazardous IVs, protecting both their patients and their staff from exposure risks.

13 Aug 2010

NewCardio second-quarter net loss decreases to $1.5 million

NewCardio, Inc., a cardiac diagnostic technology provider, today announced financial results for the second quarter ended June 30, 2010.

13 Aug 2010

Mercator signs license agreement with MD Anderson Cancer Center and closes $2.0 million seed round

Mercator Therapeutics, the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs, today announced the signing of a license agreement with The University of Texas MD Anderson Cancer Center and the closing of a $2.0 million seed round.

13 Aug 2010

New implantable device to prevent sudden cardiac arrest

Northwestern Memorial Hospital heart rhythm specialists recently gave a 34-year-old man a makeshift paramedic—who's always on duty—inside of his chest by implanting a device that did not require X-ray assistance and the usual snaking of wires leading to the heart. In fact, the innovative device rests just beneath the surface of the skin and its components are positioned using the patient's own anatomical landmarks.

13 Aug 2010

Neurologix second-quarter net loss increases to $4.5 million

Neurologix, Inc., a biotechnology company developing innovative gene therapies for the brain and central nervous system, today reported its financial results for the three and six months ended June 30, 2010.

13 Aug 2010

Epitomics spins-out Apexigen to develop and commercialize humanized rabbit monoclonal antibodies

Epitomics, Inc. today announced that it has spun-out to its shareholders a new biotechnology company called Apexigen, Inc., which will focus on the development and commercialization of humanized monoclonal antibodies for treatment of cancer and immuno-disorders.

13 Aug 2010

Kibow to support KDAE week for educating policymakers about kidney disease

Kibow Biotech would like to show its support for Kidney Disease Awareness and Education (KDAE) Week 2010, organized by American Nephrology Nurses' Association (ANNA). Kidney Disease Awareness and Education Week is a week dedicated to educating policymakers and their staff members about the needs of patients suffering from or at risk for end stage renal disease (ESRD).

13 Aug 2010

Guided Therapeutics second-quarter service revenue increases to $0.8 million

Guided Therapeutics, Inc. today announced its operating results for the second quarter and first six months of 2010.

13 Aug 2010

CLC bio, PSSC Labs announce new turnkey solution for full-genome assembly and analysis

Today, CLC bio and PSSC Labs announced a new turnkey solution, CLC Genomics Factory, for assembly, read mapping, and subsequent downstream analysis of very large amounts of high-throughput DNA and RNA sequencing data. Built as a high-performance bioinformatics appliance, CLC Genomics Factory comes in three different sizes with varying numbers of compute nodes, capable of processing the data output from up to 10 Illumina HiSeq2000 or 7 Life Technologies SOLiD 4 systems.

13 Aug 2010

Stanley awards $15 million to provide operation, infrastructure support for Nationwide Health Information Network

Stanley, Inc., a leading provider of systems integration and professional services to the U.S. federal government, today announced that it was awarded two time-and-materials contracts valued at $15 million, with exercise of options, by the U.S. Department of Health and Human Services (DHHS), Office of the National Coordinator (ONC). These two awards follow an award from DHHS that the company announced on August 2, 2010, to provide operation and infrastructure support for the Nationwide Health Information Network. All three awards fall under the company's Chief Information Officer – Solutions and Partners 2 Innovations contract with the National Institutes of Health Information Technology Acquisition and Assessment Center (NITAAC).

13 Aug 2010

Sandata announces acquisition of Medical Management Technology Group's customer base

Sandata Technologies, LLC, a leading nationwide provider of information technology solutions to the home healthcare and social services communities today announced the acquisition of all of the home healthcare agency contracts of Medical Management Technology Group, Inc. in connection with the settlement of a patent infringement lawsuit.

13 Aug 2010

ARMC completes system-wide conversion to Masimo rainbow technology

Arrowhead Regional Medical Center (ARMC) in Colton, California, and Masimo, the inventor of Masimo rainbow Pulse CO-Oximetry, Masimo rainbow Acoustic Monitorin, and Masimo SET Measure-Through Motion and Low Perfusion pulse oximetry, today jointly announced the completion of ARMC's system-wide conversion to Masimo rainbow technology.

13 Aug 2010

PyroTITAN Humeral Resurfacing shoulder implant extends longevity of hemiarthroplasty joint replacement

Ascension Orthopedics, Inc., the world leader in PyroCarbon orthopedic implants, announces the implantation of an additional PyroTITAN Humeral Resurfacing Implant in Brisbane, Australia. The PyroTITAN was implanted last month at the Brisbane Private Hospital.

13 Aug 2010

Cancer Research Technology grants Valirx global rights to develop VAL 201 for cancer treatment

Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.

13 Aug 2010

Technology News and Research

Quick-Med Technologies, Biosara sign development agreement

PROFIT magazine ranks Prollenium as one of Canada's Fastest Growing Companies

SANUWAVE second-quarter revenues decrease to $117,000

First Edition: August 13, 2010

General Dynamics awarded $80.3M contract to support HHS Early Retiree Reinsurance Program

EUROPEAN BIOTECHNICA AWARD finalists announced

UMass Memorial selects McKesson's CytoCare robot to automate compounding of hazardous IV drugs

NewCardio second-quarter net loss decreases to $1.5 million

Mercator signs license agreement with MD Anderson Cancer Center and closes $2.0 million seed round

New implantable device to prevent sudden cardiac arrest

Neurologix second-quarter net loss increases to $4.5 million

Epitomics spins-out Apexigen to develop and commercialize humanized rabbit monoclonal antibodies

Kibow to support KDAE week for educating policymakers about kidney disease

Guided Therapeutics second-quarter service revenue increases to $0.8 million

CLC bio, PSSC Labs announce new turnkey solution for full-genome assembly and analysis

Stanley awards $15 million to provide operation, infrastructure support for Nationwide Health Information Network

Sandata announces acquisition of Medical Management Technology Group's customer base

ARMC completes system-wide conversion to Masimo rainbow technology

PyroTITAN Humeral Resurfacing shoulder implant extends longevity of hemiarthroplasty joint replacement

Cancer Research Technology grants Valirx global rights to develop VAL 201 for cancer treatment

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News